← Leaderboards
Eric D Lazartigues
Lsu Health Sciences Center
$11,805,231
Attributed
$16,260,002
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,260,002 · 10
VA$0 · 3
By mechanism
R01$14,762,085 · 5
R21$1,066,194 · 2
P20$431,723 · 3
I01$0 · 2
IK6$0 · 1
Top collaborators
- Jason Davin Gardner6 shared
- Xinping Yue6 shared
- Catalin Filipeanu2 shared
- Abraam M. Yakoub2 shared
- Chien-Te K Tseng1 shared
Most similar at Lsu Health Sciences Center
Same institution · by research overlap
- Jason Davin Gardner$1,371,131
- Anna Kathryn Whitehead$131,182
- Scott Edwards$5,298,686
Others in their field
Top investigators on “Renin-Angiotensin System”
- S Michael Mauer · University Of Minnesota Twin Cities$23,372,766
- Jonathan Himmelfarb · Maine Medical Center$19,069,830
- Curt Daniel Sigmund · Medical College Of Wisconsin$17,278,162
- Alessandro Doria · Joslin Diabetes Center$16,452,875
- Dan M Roden · Vanderbilt University Medical Center$13,619,422
- Michal Laniado Schwartzman · New York Medical College$13,259,109
Research focus
Renin-Angiotensin SystemCardiovascular SystemBrainHypertensionMolecularReceptorCardiovascular DiseasesPeptidyl-Dipeptidase AMediatingAffectIn VivoAngiotensin IiHypertension TreatmentPreventNeuronsPeptidesTransgenic OrganismsBlood PressureMaintenanceMemberAngiotensin I (1-7)LeadReportingMedical
Grant awards (43)
Targeting ADAM17 maturation in resistant hypertension.$549,262
R01 · FY2025 · HL · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Targeting ADAM17 maturation in resistant hypertension.$538,276
R01 · FY2024 · HL · contact PI
Targeting ACE2 ubiquitination for hypertension$600,541
R01 · FY2023 · HL · contact PI
Targeting ADAM17 maturation in resistant hypertension.$549,262
R01 · FY2023 · HL · contact PI
Targeting ACE2 ubiquitination for hypertension$600,541
R01 · FY2022 · HL · contact PI
Targeting ADAM17 maturation in resistant hypertension.$578,289
R01 · FY2022 · HL · contact PI
COVID19: SARS-CoV-2 and ACE2 interaction in hypertension$0
I01 · FY2022 · VA · contact PI
SARS-CoV-2 tropism in the brain and its relationship to COVID-19 pathogenesis$3,672,336
R01 · FY2021 · HL
SARS-CoV-2 tropism in the brain and its relationship to COVID-19 pathogenesis$642,597
R01 · FY2021 · HL
Targeting ACE2 ubiquitination for hypertension$600,541
R01 · FY2021 · HL · contact PI
Chronic nicotine inhalation increases susceptibility to cardiovascular and pulmonary diseases through inhibition of local compensatory mechanisms$396,097
R01 · FY2021 · HL
New strategies to restore ACE2 compensatory activity in neurogenic hypertension$0
I01 · FY2021 · VA · contact PI
COVID19: SARS-CoV-2 and ACE2 interaction in hypertension$0
I01 · FY2021 · VA · contact PI
Targeting ACE2 ubiquitination for hypertension$633,177
R01 · FY2020 · HL · contact PI
Chronic nicotine inhalation increases susceptibility to cardiovascular and pulmonary diseases through inhibition of local compensatory mechanisms$404,754
R01 · FY2020 · HL
Chronic nicotine inhalation increases susceptibility to cardiovascular and pulmonary diseases through inhibition of local compensatory mechanisms$312,700
R01 · FY2020 · HL
New strategies to restore ACE2 compensatory activity in neurogenic hypertension$0
I01 · FY2020 · VA · contact PI
Chronic nicotine inhalation increases susceptibility to cardiovascular and pulmonary diseases through inhibition of local compensatory mechanisms$413,160
R01 · FY2019 · HL
New strategies to restore ACE2 compensatory activity in neurogenic hypertension$0
I01 · FY2019 · VA · contact PI
Chronic nicotine inhalation increases susceptibility to cardiovascular and pulmonary diseases through inhibition of local compensatory mechanisms$421,318
R01 · FY2018 · HL
New strategies to restore ACE2 compensatory activity in neurogenic hypertension$0
I01 · FY2018 · VA · contact PI
Chronic nicotine inhalation increases susceptibility to cardiovascular and pulmonary diseases through inhibition of local compensatory mechanisms$411,990
R01 · FY2017 · HL
Mechanisms of ACE2 Regulation in Neurogenic Hypertension$375,831
R01 · FY2017 · HL · contact PI
Mechanisms of ACE2 Regulation in Neurogenic Hypertension$375,831
R01 · FY2016 · HL · contact PI
Mechanisms of ACE2 Regulation in Neurogenic Hypertension$370,194
R01 · FY2015 · HL · contact PI
Mechanisms of ACE2 Regulation in Neurogenic Hypertension$375,831
R01 · FY2014 · HL · contact PI
Brain-targeted ACE2 over-expression on angiotensin-II-mediated hypertension$351,450
R01 · FY2012 · HL · contact PI
Brain-targeted ACE2 over-expression on angiotensin-II-mediated hypertension$355,000
R01 · FY2011 · HL · contact PI
Effects of ACE2 gene therapy on Diabetes$168,217
R21 · FY2011 · DK · contact PI
Brain-targeted ACE2 over-expression on angiotensin-II-mediated hypertension$355,000
R01 · FY2010 · HL · contact PI
Effects of ACE2 gene therapy on Diabetes$202,064
R21 · FY2010 · DK · contact PI
Brain-targeted ACE2 over-expression on angiotensin-II-mediated hypertension$355,000
R01 · FY2009 · HL · contact PI
Brain-targeted ACE2 over-expression on angiotensin-II-mediated hypertension$168,107
R01 · FY2009 · HL · contact PI
P7: BRAIN-TARGETED ACE2 OVEREXPRESSION AND BLOOD PRESSURE REGULATION$55,511
P20 · FY2009 · RR · contact PI
Brain-targeted ACE2 over-expression on angiotensin-II-mediated hypertension$355,000
R01 · FY2008 · HL · contact PI
Central ACE2, Blood Pressure Regulation and Hypertension$206,055
R21 · FY2008 · NS · contact PI
P7: BRAIN-TARGETED ACE2 OVEREXPRESSION AND BLOOD PRESSURE REGULATION$169,294
P20 · FY2008 · RR · contact PI
P7: BRAIN-TARGETED ACE2 OVEREXPRESSION AND BLOOD PRESSURE REGULATION$206,918
P20 · FY2007 · RR · contact PI
Central ACE2, Blood Pressure Regulation and Hypertension$189,061
R21 · FY2007 · NS · contact PI
Central ACE2, Blood Pressure Regulation and Hypertension$50,058
R21 · FY2007 · NS · contact PI
Central ACE2, Blood Pressure Regulation and Hypertension$28,941
R21 · FY2006 · NS · contact PI
Central ACE2, Blood Pressure Regulation and Hypertension$221,798
R21 · FY2005 · NS